Compounds > erlotinib hydrochloride
Page last updated: 2024-09-05

erlotinib hydrochloride and buparlisib

erlotinib hydrochloride has been researched along with buparlisib in 3 studies

Compound Research Comparison

Studies
(erlotinib hydrochloride)		Trials
(erlotinib hydrochloride)		Recent Studies (post-2010)
(erlotinib hydrochloride)		Studies
(buparlisib)		Trials
(buparlisib)		Recent Studies (post-2010) (buparlisib)
4,3537863,03325648252

Protein Interaction Comparison

ProteinTaxonomyerlotinib hydrochloride (IC50)buparlisib (IC50)
Chain A, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoformHomo sapiens (human)0.262
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformRattus norvegicus (Norway rat)0.117
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)0.1363
Cytochrome P450 1A2Homo sapiens (human)0.011
Cytochrome P450 3A4Homo sapiens (human)0.027
Cytochrome P450 2C8Homo sapiens (human)0.04
Cytochrome P450 2B6Homo sapiens (human)0.011
Phosphatidylinositol 3-kinase regulatory subunit alphaHomo sapiens (human)0.0878
Cytochrome P450 2C19Homo sapiens (human)0.372
Aldo-keto reductase family 1 member C3Homo sapiens (human)8.7
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)0.055
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)0.2507
Serine/threonine-protein kinase mTORHomo sapiens (human)1.9814
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)0.5654
DNA-dependent protein kinase catalytic subunitHomo sapiens (human)6.917
Phosphatidylinositol 3-kinase catalytic subunit type 3Homo sapiens (human)2.4905
Phosphoinositide 3-kinase regulatory subunit 5Homo sapiens (human)0.129
Serine/threonine-protein kinase mTOR Mus musculus (house mouse)0.832
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformRattus norvegicus (Norway rat)0.523

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Antonakos, B; Cooke, VG; Danial, NN; Flemming, D; Hurov, KE; Jones, MD; Korn, JM; Ledell, J; Lehár, J; Mishina, Y; Schoumacher, M; Sellers, WR; Shao, W; Sonkin, D; Steiger, J; Stump, MD; Yan-Neale, Y1
Alagesan, B; Bardeesy, N; Benes, CH; Contino, G; Corcoran, RB; Deshpande, V; Engelman, J; Guimaraes, AR; Hezel, AF; Loda, M; Weissleder, R; Wojtkiewicz, GR; Wong, KK1
Amin, AR; Anisuzzaman, AS; Chen, Z; Chen, ZG; Haque, A; Rahman, MA; Shin, DM; Wang, D; Zhang, C1

Other Studies

3 other study(ies) available for erlotinib hydrochloride and buparlisib

ArticleYear
Inhibiting Tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling.
    Cancer research, 2014, Jun-15, Volume: 74, Issue:12

    Topics: Acetamides; Aminopyridines; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Erlotinib Hydrochloride; Feedback, Physiological; Female; Humans; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Morpholines; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrimidinones; Quinazolines; ras Proteins; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Sulfonamides; Tankyrases; Thiazoles; Xenograft Model Antitumor Assays

2014
Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Jan-15, Volume: 21, Issue:2

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Disease Models, Animal; Drug Screening Assays, Antitumor; Drug Synergism; Erlotinib Hydrochloride; Humans; MAP Kinase Kinase Kinases; Mice, Transgenic; Morpholines; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines

2015
    Molecular cancer therapeutics, 2017, Volume: 16, Issue:4

    Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cytoprotection; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Mice; Morpholines; Proto-Oncogene Proteins c-akt; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2017